Abstract
Present treatment options for hepatocellular cancer (HCC) are limited to those individuals with good liver function and early stage disease. Unfortunately this includes only a minority of patients, few of which are actually cured of their cancer. Over the last 15-20 years biotechnology has made a very significant impact on medical research, to the extent that we know very much more about the regulation of normal cell growth and death, as well as the mechanisms underlying its disruption in disease processes. This knowledge has and is being rapidly exploited by academic and pharmaceutical organisations, often in collaboration. The result is the development, testing and steady introduction of therapies that target specific abnormalities in cancer cells. Although the safety and effectiveness of the majority of these agents has yet to be established in cirrhotic patients with HCC, we are hopeful that we will shortly see an increase in effective treatment options available for clinical use this disease. This review focuses on aberrant cancer proteins and pathways relevant to HCC, as well as the novel therapies or strategies targeting them, that are currently in the development or testing stages.
Keywords: Hepatocellular Cancer, new therapies, molecular targets, small molecule inhibitors, receptor tyrosine kinase
Current Pharmaceutical Design
Title: The Development of Targeted Therapies for Hepatocellular Cancer
Volume: 13 Issue: 32
Author(s): D. Chattopadhyay, D. M. Manas and H. L. Reeves
Affiliation:
Keywords: Hepatocellular Cancer, new therapies, molecular targets, small molecule inhibitors, receptor tyrosine kinase
Abstract: Present treatment options for hepatocellular cancer (HCC) are limited to those individuals with good liver function and early stage disease. Unfortunately this includes only a minority of patients, few of which are actually cured of their cancer. Over the last 15-20 years biotechnology has made a very significant impact on medical research, to the extent that we know very much more about the regulation of normal cell growth and death, as well as the mechanisms underlying its disruption in disease processes. This knowledge has and is being rapidly exploited by academic and pharmaceutical organisations, often in collaboration. The result is the development, testing and steady introduction of therapies that target specific abnormalities in cancer cells. Although the safety and effectiveness of the majority of these agents has yet to be established in cirrhotic patients with HCC, we are hopeful that we will shortly see an increase in effective treatment options available for clinical use this disease. This review focuses on aberrant cancer proteins and pathways relevant to HCC, as well as the novel therapies or strategies targeting them, that are currently in the development or testing stages.
Export Options
About this article
Cite this article as:
Chattopadhyay D., Manas M. D. and Reeves L. H., The Development of Targeted Therapies for Hepatocellular Cancer, Current Pharmaceutical Design 2007; 13 (32) . https://dx.doi.org/10.2174/138161207782360717
DOI https://dx.doi.org/10.2174/138161207782360717 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Ubiquitylation and Cancer Development
Current Cancer Drug Targets Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Cell-Penetrating Peptides: Mechanisms and Applications
Current Pharmaceutical Design Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry MEET THE GUEST EDITOR [Hot Topic: Modern Omics-Based Platform for High Throughput Screening for Novel Drug Targets (Part 2) (Guest Editor: Canhua Huang)]
Combinatorial Chemistry & High Throughput Screening Two Promising Anti-Cancer Compounds, 2-Hydroxycinnaldehyde and 2- Benzoyloxycinnamaldehyde: Where do we stand?
Combinatorial Chemistry & High Throughput Screening Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg
Protein & Peptide Letters Sugar Based Biopolymers in Nanomedicine; New Emerging Era for Cancer Imaging and Therapy
Current Topics in Medicinal Chemistry Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology Synthesis and Biological Evaluation of New Pyrazole-based Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery The Targets of Curcumin
Current Drug Targets Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Current Cancer Drug Targets